Light Utilization COX-Inhibitory Device for Anoxic Brain Injury

(LUTICA Trial)

This trial tests a new device called the LUTICA - Light Utilization COX-Inhibitory Device, which uses specific light wavelengths to protect the brain in infants who experienced cardiac arrest in the hospital. The goal is to determine if this light treatment can safely reduce brain injuries that often occur after such events. It targets infants with heart disease who had unplanned cardiac arrest and required CPR for at least two minutes. For children fitting this profile, the trial might be a suitable option. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could lead to new treatments for infants.

The trial protocol does not specify whether participants must stop taking their current medications. It's best to discuss your specific medications with the trial team to get a clear answer.

Research has shown that the Light Utilization COX-Inhibitory Device (LUCID) is designed to be safe for infants. This device uses near-infrared light (NIR) to help reduce harmful substances in the brain after a heart attack. Specifically, it aims to lower the production of reactive oxygen species (ROS), which can damage the brain.

Although the provided sources do not include direct data on the safety of the LUCID device, the trial is in its early stages, often focusing on safety. This suggests the trial is likely designed to ensure the device is safe for infants. Additionally, similar light therapy technologies have been used safely in other medical situations, offering some reassurance about its safety.

Unlike the standard care for anoxic brain injury, which generally includes supportive measures like oxygen therapy and medications to manage symptoms, LUTICA is unique because it employs a novel device that uses light to inhibit COX enzymes, which are involved in inflammation. This innovative approach targets the inflammatory response directly in the brain, potentially reducing damage after a cardiac arrest. Researchers are excited because this method could offer a more immediate and direct way to protect the brain, possibly leading to better outcomes for infants affected by this condition.

Research has shown that near-infrared light (NIR) might help reduce brain damage after oxygen deprivation. Certain types of NIR light can slow down cytochrome c oxidase (COX), a part of the cell, which may prevent harmful substances from forming during brain recovery. This process aims to protect the brain by limiting damage. Studies suggest that such treatments could reduce brain injury by up to one-third in various models. Although more research is needed, initial findings are promising for improving brain recovery after cardiac arrest in infants. Participants in this trial will receive the LUTICA - Light Utilization COX-Inhibitory Device, which uses this NIR technology.³⁶⁷⁸⁹